Conference Program

Dr Sergey a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980. Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences, National Center for Immunology (Russia), NIH, Bethesda, USA, and British Society forImmunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Professor of I.M. Sechenov First Moscow State Medical University and of A.I.Evdokimov Moscow State Medical & Dental University. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Dis-eases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Person-alized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology, EPMA J., and Personalized Medicine Universe, and others. Now Suchkov is a Chair of Dept for Personalized & Translational Medicine, and Director, Center for Personalized & Translational Reproductology, I.M.Sechenov First Moscow State Medical University. Prof Sergey Suchkov, MD, PhD Chair, Dept for Personalized and Translational Medicine, Director, Center for Personalized Reproductology & Pediatrics, I.M.Sechenov First Moscow State Medical University, Moscow, Russia Member, EPMA, Brussels, EU Member, PMC, Washington, DC, USA Member, ISPM, Tokyo, Japan Member, New York Academy of Sciences Member, ACS, USA Member, AHA, USA Member, AMEE, Dundee, UK Secretary General, UCC, Cambridge, UK.

 i-Pharma Congress-Speaker-Sergey Suchkov

Sergey SuchkovRussia, Russia

Fan Fan is an Associate Professor at University of Mississippi Medical Center, USA. Her lab has used multidisciplinary approaches with an array of techniques to investigate how microvascular dysfunction contributes to end-organ damage, including vascular cognitive impairment, Alzheimer's disease-related dementias (ADRD), stroke, and renal disease, especially with aging, hypertension, and diabetes.

i-Pharma-Congress-Fan Fan-Speaker

Fan FanUniversity of Mississippi Medical Center, USA

Hongwei Yu is a Professor at the Medical College of Wisconsin, USA. His research interest includes gene and molecular therapy for chronic pain. His research focuses on designing, cloning, production, and application of recombinant adeno-associated viral (AAV) vectors to manipulate genes of interests in vivo in the peripheral sensory nervous system for studying pain molecular mechanism and for treating chronic pain.

Speaker-Hongwei Yu-iPharma-Congress

Hongwei YuMedical College of Wisconsin, USA

Airway organoids can be generated from primary airway epithelial cells and can recapitulate the organization and key functions of the epithelium in vivo. These properties render them an attractive alternative to the Air-Liquid Interface (ALI) cell culture model, although the closed architecture of the organoids with the apical side facing the lumen limits their application in assays requiring apical-specific interactions, such as host-pathogen interactions. To address this limitation, we have developed the PneumaCult Apical-Out Airway Organoid Medium, which is used in an ECM-free workflow that promotes generation of a large number of airway organoids that expose their apical surface to the environment. Apical out airway organoids (Ap-O AO) are composed of basal and ciliated cells and display reproducible morphology, organization and functional characteristics of the airway epithelium. Ap-O AO are susceptible to infection with common airway viruses such as Influenza A, Influenza B, Rhinovirus A16, and Enterovirus D68, and produce high viral RNA titers and have readily observable cytopathogenic effects (CPE). Treatment of Ap-O AO with two antiviral drugs, Rupintrir and Itraconazole, following infection with Enterovirus D68 demonstrates that this organoid system is also able to model the inhibitory effects of drug in vitro. In summary, PneumaCult Apical-Out Airway Organoid Medium supports the efficient and reproducible generation of apical out airway organoids that are susceptible to viral infections and show high potential for supporting high-throughput downstream applications.

Salvatore Simmini-Speaker-STEMCELL Technologies

Salvatore SimminiSTEMCELL Technologies , UK

Milan Sen?anski currently holds the position of Senior Research Associate at Vinca Institute of Nuclear Sciences in Belgrade, Serbia. He received his PhD in Physical Chemistry in 2011 at University of Belgrade, Serbia. His research interests include various in silico approaches as tools in the discovery of new ligands or drug repurposing for chronic and infectious diseases.

i-Pharma Congress-Speaker-Milan-Sencanski

Milan SencanskiVinca Institute of Nuclear Sciences , Serbia

Prof. Daniela Monti graduated in Chemistry and Pharmaceutical Technology and received the PhD in "Design, Development and Bio-­?evaluation of Drugs". In 2000, she became Assistant Professor of Pharmaceutical Technology and currently she holds the role of Associate Professor at the Department of Pharmacy, University of Pisa. Her scientific research is oriented towards the study of drug delivery systems to the cutaneous, ungual, ocular, vaginal and buccal site, the use of cell cultures to evaluate toxicity on corneal epithelium cells of ophthalmic excipients and the cosmetic field. From 1997 to 2000 he participated in the European project BIOMED-­?2, (BMH4-­?97-­?2324) entitled "Evaluation of oculotoxicity of drugs in vitro" with the following European partners: University of Tampere (Finland), University of Bremen (Germany), University of Ioannina (Greece), Orion Corporation Ltd. and Oy Star AB, (Finland). She is also responsible for several research projects involving international companies. Furthermore, she is the author of many publications in international journals with referee, of patents and presented her research at national and international meetings. She has been reviewer for many scientific journals.

i-Pharma Congress-Daniela-Monti-Italy

Daniela MontiUniversity of Pisa, Italy

Xolani Henry Makhoba currently works as a Senior Lecturer and Researcher at the University of Fort-Hare under the Department of Biochemistry and Microbiology. He's involved in malaria research, searching for alternative vaccines or drugs for malaria. He’s also involved in diabetes research looking for innovative ways to speed up wound healing in diabetic patients (in collaboration with the George Washington DC University). Dr. Makhoba is in collaboration with the University of Oxford is also involved in SARS-CoV-2 project looking at innovative strategies to halt the virus to hijack human host cells folding machinery. Dr. Makhoba has established several collaborations both local and international with intentions to exchange knowledge in the field of science. He has a strong background in cell biology, plant biochemistry/biology, cell or tissue culture, molecular biology, biotechnology, bioinformatics, next-generation sequences, real-time PCR just to name a few. He's involved in post-graduate supervision and has been involved in curriculum development in the department. He has the potential to raise funding from external sources. He was previously funded by research development program (RDP) and currently funded by SA-MRC (2022-2024). Dr. Makhoba serves in several committees in the Department (Biochemistry and Microbiology). He has served in various panels at National Research Foundation (NRF). He is also holding membership in the International Biochemistry Society.

i-Pharma Congress- Speaker-Xolani Henry Makhoba

Xolani Henry MakhobaUniversity of Fort Hare, South Africa

Islam M. Adel is an assistant lecturer of Pharmaceutics and Industrial Pharmacy at Faculty of pharmacy, Cairo University. He studied pharmaceutical sciences at Faculty of pharmacy, Cairo University . Adel has his expertise in the formulation and evaluation of scaffolds and nanoparticles together with reviews in the field of inhalation drug delivery and scaffold fabrication techniques.

i-Pharma Congress-Islam Mohamed Adel Mahmoud Hashim-Speaker

Islam Mohamed Adel Mahmoud HashimCairo University, Egypt

To be updated soon

i-Pharma-Congress-Speaker-Ayed Awad Dera

Ayed Awad DeraKing Khalid University, Saudi Arabia

Abstract: Covid-19 pandemic has escalated the use of surgical mask and N95 mask across the globe that takes hundreds of years to degrade and finally end up as micro plastics in soil. In this work we report recycling of used surgical mask, N95 mask into white light emitting carbon dots (CDs). Further the fabricated CDs are characterized using UV-absorption emission spectroscopies. Using our unique recycling technique, broadband single system white light emitting CDs with broad absorption and emission bandwidth of ~ 143 nm and ~124 nm are fabricated using used surgical mask and N95 mask respectively. This work will address the issue of plastic waste pollution and these dots find applications as active emitters in artificial lighting devices.

i-Pharma Congress-Speaker

Manasa Perikala IISc Bangalore, India